bluebird bio, Inc. Forecasted to Earn Q1 2025 Earnings of ($0.46) Per Share (NASDAQ:BLUE)

bluebird bio, Inc. (NASDAQ:BLUE) – Stock analysts at William Blair issued their Q1 2025 earnings per share estimates for bluebird bio in a report released on Tuesday, March 26th. William Blair analyst S. Corwin forecasts that the biotechnology company will post earnings of ($0.46) per share for the quarter. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for bluebird bio’s current full-year earnings is ($1.78) per share. William Blair also issued estimates for bluebird bio’s Q2 2025 earnings at ($0.34) EPS.

Several other research firms also recently commented on BLUE. HSBC dropped their price target on shares of bluebird bio from $2.31 to $1.02 and set a “reduce” rating for the company in a research note on Tuesday, March 5th. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $6.00 target price on shares of bluebird bio in a report on Wednesday. Morgan Stanley raised shares of bluebird bio from an “underweight” rating to an “equal weight” rating and increased their price objective for the company from $3.00 to $7.00 in a research report on Friday, December 8th. Bank of America cut their price target on bluebird bio from $12.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday, December 21st. Finally, Wedbush cut their target price on bluebird bio from $1.72 to $1.68 and set a “neutral” rating on the stock in a research report on Tuesday, March 19th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $5.87.

bluebird bio Trading Up 13.8 %

Shares of NASDAQ:BLUE opened at $1.37 on Thursday. The firm’s 50-day moving average is $1.24 and its two-hundred day moving average is $2.28. bluebird bio has a 1 year low of $0.88 and a 1 year high of $5.53.

Institutional Investors Weigh In On bluebird bio

Several institutional investors have recently made changes to their positions in BLUE. State Street Corp boosted its stake in shares of bluebird bio by 597.0% during the 3rd quarter. State Street Corp now owns 12,720,480 shares of the biotechnology company’s stock worth $80,521,000 after acquiring an additional 10,895,379 shares in the last quarter. Norges Bank purchased a new position in bluebird bio during the 4th quarter valued at about $5,514,000. Granahan Investment Management LLC increased its stake in shares of bluebird bio by 236.0% during the 2nd quarter. Granahan Investment Management LLC now owns 4,856,322 shares of the biotechnology company’s stock worth $15,977,000 after purchasing an additional 3,411,065 shares in the last quarter. Palo Alto Investors LP purchased a new stake in bluebird bio in the 4th quarter valued at approximately $4,600,000. Finally, Vanguard Group Inc. raised its holdings in shares of bluebird bio by 56.2% in the fourth quarter. Vanguard Group Inc. now owns 8,775,379 shares of the biotechnology company’s stock worth $12,110,000 after acquiring an additional 3,157,919 shares during the last quarter. 87.43% of the stock is currently owned by hedge funds and other institutional investors.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.